Comments on:

Actavis, Noven reach settlement in Daytrana patent case

Back to the article » |
Parsippany, N.J. (Legal Newsline) — Actavis plc announced Wednesday it has settled with Noven Pharmaceuticals Inc. in a case over Actavis’ generic version of the medication Daytrana. Actavis said in a statement that the agreement will settle all outstanding patent litigation related to the drug, a stimulant often used to treat Attention Deficit Hyperactivity Disorder, or ADHD, and...

To learn more about commenting on WashingtonExaminer.com and our community guidelines, please see our comments FAQ.